Fairvalue-Calculator Fairvalue-Calculator
EN DE

EstechPharma Co (041910) Fair Value & Analysis

Healthcare · KR · Market cap 73.6B KRW

Price4,645 KRW
Fair Value8,679 KRW
Upside+86.8%
Quality95/100
Evidence: High Range 6,135 KRW – 9,753 KRW

Fair value as of: Jun 24, 2026

Analysis

EstechPharma Co (041910) currently trades at 4,645 KRW, while our model-based Fair Value estimate is 8,679 KRW — implying the stock looks roughly 86.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

EstechPharma Co., Ltd. manufactures and sells pharmaceuticals products. It also offers raw materials, such as RBM and PLK. The company was formerly known as Estech Chemical and changed its name to EstechPharma Co., Ltd. in January 2001. EstechPharma Co., Ltd. was founded in 1996 and is headquartered in Hwaseong-si, South Korea.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is EstechPharma Co (041910) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 8,679 KRW versus a price of 4,645 KRW — about +87% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 041910?
Our 21-model fair value for EstechPharma Co is 8,679 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 4,645 KRW.
What is the quality score of 041910?
EstechPharma Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.